AZD9574 CAS No.:2756333-39-6

AZD9574 CAS No.:2756333-39-6 is an innovative chemical compound that has caught the attention of many merchants around the world who seek high-quality products at a reasonable cost. This product, developed in China, is an inhibitor of the CXCR4 receptor that shows significant potential in the treatment of a wide range of cancers.

The CXCR4 receptor, also known as C-X-C chemokine receptor type 4, is a protein that plays a crucial role in the spread of cancer cells. It is present in many different types of cancer, including breast, prostate, lung, and colon cancer, among others. By inhibiting this protein, AZD9574 is able to slow down or stop the spread of cancer cells, leading to increased survival rates and improved quality of life for cancer patients.

But AZD9574 is not just an inhibitor of the CXCR4 receptor. It also has other activities that make it a promising candidate for future therapeutic use. For example, AZD9574 has been shown to activate the immune system, which can help the body's natural defense mechanisms fight cancer. Additionally, it has been found to have anti-inflammatory properties, which may be useful in the treatment of several diseases.

When it comes to selling AZD9574 to merchants outside of China, there are several aspects that can be highlighted to attract their attention. Firstly, this product is of high quality, having been developed by experts in the field of pharmaceuticals. These experts have conducted extensive research to ensure that the compound's properties are well-understood and that it is safe for use in humans.

Secondly, AZD9574 is available at a reasonable cost. This makes it an attractive option for merchants who are looking to provide their customers with effective cancer treatments without breaking the bank. With the rising costs of healthcare in many countries, AZD9574 offers a cost-effective alternative that can help improve patient outcomes while also managing costs.

Thirdly, AZD9574 is versatile in terms of its potential applications. While its primary use may be in the treatment of cancer, its other properties make it a promising candidate for other disease states. The compound has been shown to be effective against inflammation, which may make it useful in the treatment of diseases such as rheumatoid arthritis and multiple sclerosis. Additionally, its ability to activate the immune system may make it useful in the treatment of viral infections.

In summary, AZD9574 is an innovative product that has significant potential in the treatment of cancer and other diseases. Its high quality, reasonable cost, and versatility make it an attractive option for merchants outside of China who are looking to offer their customers high-quality, cost-effective treatments. By highlighting these aspects, you can help to attract merchants and increase sales of this innovative product.

Chemical Structure : AZD9574

CAS No.: 2756333-39-6

 

AZD9574(AZD-9574)

Catalog No.: URK-V2330  Only Used For Lab.

AZD9574 (AZD-9574) is a potent, selective and CNS penetrant PARP1 inhibitor, inhibits PARP1 enzymatic activity with IC50 of 0.3-2.0 nM in a panel of cell lines irrespective of the HRR status.

Biological Activity

AZD9574 (AZD-9574) is a potent, selective and CNS penetrant PARP1 inhibitor, inhibits PARP1 enzymatic activity with IC50 of 0.3-2.0 nM in a panel of cell lines irrespective of the HRR status.
AZD9574 acts by selectively inhibiting and trapping PARP1 at the sites of SSBs.
AZD9574 exhibits >8000-fold selectivity for PARP1 compared to PARP2 and other members of the PARP family (PARP2, PARP3, PARP5a and PARP6) in biochemical assays.
AZD9574 inhibits colony formation assay in isogenic cell lines pairs confirmed higher potency and selectivity towards HRD+ models (DLD1 BRCA2-/-; SKOV-3 BRCA2-/- and SKOV-3 PALB2-/-), inhibits BRCA2-/- DLD1 cells with IC50 of 1.38 nM, and shows no effect against BRCA2wt cells.
AZD9574 demonstrated dose-dependent efficacy in a BRCA1 mutant MDA-MB-436 subcutaneous xenograft model. AZD9574 (3 mg/kg) showed sustained tumour growth suppression resulting in a significantly extended survival of tumour-bearing intracranial xenograft model of breast cancer brain metastases.

Physicochemical Properties

References

1. Kunzah Jamal, et al. Cancer Res (2022) 82 (12_Supplement): 2609.

URK-V2330_COA

URK-V2330_SDS

URK-V2330_TDS

 

Note: All products of Ureiko are only used for scientific research or drug certificate declaration, and we do not provide products and services for any personal use!

Why choose us?

• We believe in building long-term relationships with our customers based on trust and mutual benefit.
• Our rapid development in recent years has benefited from a large number of innovative talents in technology, sales and management.
• We have established long-term relationships with our suppliers to ensure consistent product quality.
• We are committed to cultivating a talent team with reasonable structure, excellent quality and continuous growth to meet the company's strategic development needs.
• We are committed to providing our customers with the best possible experience, from the ordering process to delivery and support.
• We provide customers with the most valuable brands, products that best meet customer needs, and services that exceed expectations, and grow together with the ever-evolving country.
• We are committed to offering the best value for money to our customers.
• As a participant and witness of the development of AZD9574 CAS No.:2756333-39-6, our company has been committed to the comprehensive operation and development of AZD9574 CAS No.:2756333-39-6 for a long time, and realizes the strategic layout from regional cities to nationalization.
• Our products are perfect for research and laboratory applications.
• Since the establishment of our company, we have insisted on relying on science and technology and continuously absorbed advanced foreign technology.

Hot Tags: azd9574 cas no.:2756333-39-6, China azd9574 cas no.:2756333-39-6, epigenetic library for epigenetic regulation of cell enhancement, agonists for epigenetic regulation, epigenetic library for epigenetic activation, epigenetic library for epigenetic analysis of epigenetic dysregulation, inhibitors for enzyme activity, inhibitors for angiogenesis